News articles about Myokardia (NASDAQ:MYOK) have trended somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Myokardia earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 44.9722746752165 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- Myokardia (MYOK) Rating Increased to Buy at BidaskClub (americanbankingnews.com)
- BRIEF-Myokardia Begins Patient Dosing In Phase 1B Clinical Study Of Myk-491 (reuters.com)
- MyoKardia to Present at the RBC Capital Markets’ 2018 Healthcare Conference (finance.yahoo.com)
- MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients (finance.yahoo.com)
Several analysts have recently issued reports on the stock. BidaskClub raised shares of Myokardia from a “hold” rating to a “buy” rating in a research report on Saturday. ValuEngine raised shares of Myokardia from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Credit Suisse Group reissued an “outperform” rating and issued a $60.00 price target on shares of Myokardia in a research report on Thursday, January 18th. Zacks Investment Research lowered shares of Myokardia from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Finally, TheStreet lowered shares of Myokardia from a “c” rating to a “d+” rating in a research report on Friday, November 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $55.67.
In other Myokardia news, insider Jake Bauer sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $42.89, for a total value of $214,450.00. Following the completion of the transaction, the insider now owns 62,877 shares of the company’s stock, valued at approximately $2,696,794.53. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Anastasios Gianakakos sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $51.05, for a total transaction of $153,150.00. Following the completion of the transaction, the insider now directly owns 77,390 shares of the company’s stock, valued at approximately $3,950,759.50. The disclosure for this sale can be found here. Insiders have sold a total of 840,326 shares of company stock worth $35,376,662 in the last ninety days. 33.40% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: “Myokardia (MYOK) Receiving Somewhat Positive News Coverage, Analysis Shows” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://stocknewstimes.com/2018/02/19/myokardia-myok-receiving-somewhat-positive-news-coverage-analysis-shows.html.
Myokardia Company Profile
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.